- Home
- BBNX vs AKBA Comparison
BBNX vs AKBA Comparison
Compare BBNX & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBNX
- AKBA
- Stock Information
- Founded
- BBNX 2015
- AKBA 2007
- Country
- BBNX United States
- AKBA United States
- Employees
- BBNX N/A
- AKBA N/A
- Industry
- BBNX Medical/Dental Instruments
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- BBNX Health Care
- AKBA Health Care
- Exchange
- BBNX Nasdaq
- AKBA Nasdaq
- Market Cap
- BBNX 740.7M
- AKBA 861.7M
- IPO Year
- BBNX 2025
- AKBA 2014
- Fundamental
- Price
- BBNX $17.05
- AKBA $3.19
- Analyst Decision
- BBNX Strong Buy
- AKBA Strong Buy
- Analyst Count
- BBNX 10
- AKBA 5
- Target Price
- BBNX $24.40
- AKBA $6.90
- AVG Volume (30 Days)
- BBNX 811.1K
- AKBA 4.0M
- Earning Date
- BBNX 07-29-2025
- AKBA 08-07-2025
- Dividend Yield
- BBNX N/A
- AKBA N/A
- EPS Growth
- BBNX N/A
- AKBA N/A
- EPS
- BBNX N/A
- AKBA N/A
- Revenue
- BBNX $69,830,000.00
- AKBA $203,733,000.00
- Revenue This Year
- BBNX $32.71
- AKBA $38.23
- Revenue Next Year
- BBNX $37.37
- AKBA $38.17
- P/E Ratio
- BBNX N/A
- AKBA N/A
- Revenue Growth
- BBNX 38911.17
- AKBA 16.75
- 52 Week Low
- BBNX $8.89
- AKBA $1.24
- 52 Week High
- BBNX $24.50
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- BBNX N/A
- AKBA 41.27
- Support Level
- BBNX N/A
- AKBA $3.02
- Resistance Level
- BBNX N/A
- AKBA $3.44
- Average True Range (ATR)
- BBNX 0.00
- AKBA 0.16
- MACD
- BBNX 0.00
- AKBA -0.03
- Stochastic Oscillator
- BBNX 0.00
- AKBA 31.03
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.